medday privately-held french biotechnolog compani focus
develop treatment disord target specif metabol pathway
brain compani lead product pharmaceutical-grad high-dos biotin
formul treatment progress multipl sclerosi ms medday shown
impress result first phase studi ms-spi revers diseas progress
subset treat patientsand current conduct second phase trial ms-
confirm result larger sampl patient posit medday plan file
approv us europ given lack treatment option impact
neurodegen aspect diseas posit result would transform patient
repres major inflect point compani valuat medday also test
sever addit indic includ amyotroph later sclerosi al
also two addit preclin asset evalu autism spectrum disord
alzheim diseas
medday promis compani focus neurometabol oral formul pharmaceutical-grad high-
dose biotin current test novel approach treat progress ms dose biotin contain
higher recommend daili nutrit level thu consid activ pharmaceut ingredi
approach stem off-label use high-dos biotin treat orphan hereditari diseas known basal ganglia diseas medday
found expert field neurometabol produc pipelin drug address wide rang
condit ms particularli excit opportun compani given clear need market treatment target
neurodegener hallmark patholog progress ms compani well-fund roughli million end
receiv invest sofinnova partner edmond de rothschild bpifranc
mechan action could repres disease-modifi approach ms mechan
action progress ms patient thought involv biotin role cofactor subsequ abil activ
number biotin-depend carboxylas rate-limit enzym involv fatti acid synthesi myelin product biotin
also provid intermedi requir energi product tricarboxyl acid tca kreb cycl key aspect
ms patholog chronic demyelin caus immune-medi attack myelin sheath progress cell death neuron
enter state virtual hypoxia caus rise energi demand demyelin neuron enhanc fatti acid synthesi
energi product biotin may target two import aspect ms pathophysiolog approv treatment progress
ms roch vtx rog vx ocrevu ocrelizumab address neuroinflamm target antigen b-cell
approach effect reduc inflamm impact neurodegen process thu despit exist
treatment landscap ms remain press need therapi slow neurodegen process patient
progress ms activ inflamm
medday report posit result first phase trial medday success complet ms-spi phase
trial patient current conduct second phase studi patient support regulatori file
us europ ms-spi trial patient show confirm revers diseas progress
month compar placebo-tr patient data obtain small sampl size result
unpreced confirm larger trial could transform treatment progress ms ms-
studi similar design first phase notabl differ primari efficaci analysi follow
double-blind compar double-blind phase use ms-spi trial medday expect complet
enrol june report data decemb could pave way regulatori file result
posit could becom first approv treatment target neurodegener progress ms patient
earli access program franc provid world data use sinc made avail
progress ms patient franc earli access program via temporari author use atu program
analyst certif disclosur pleas see page
provid real world data use patient date medday report data atu may
treatment patient provid evid drug favor safeti efficaci profil atu cohort
treatment led increas mean walk distanc improv correl treatment durat
subject treat month show increas walk distanc treatment greater equal month
result improv addit concern safeti signal overal result consist data
ms-spi trial provid encourag indic drug efficaci also note atu gener
million revenu without market effort compani underscor exist need new therapi
larg market opportun address neurodegener patient ms ms common
autoimmun diseas affect roughli million diagnos individu global roughli ms patient
us estim ms patient europ vast major ms patient initi diagnos relapsing-
remit ms rrm diseas state mainli driven neuroinflamm roughli patient develop secondari
progress spm within year although sale ms drug top billion treatment option
progress ms patient roch ocrevu approv treatment sinc drug target inflamm remain
larg market opportun address neurodegener hallmark featur progress ms estim roughli
progress ms patient experi neurodegener absenc activ inflamm repres target patient
popul medday roughli individu us europ combin even modest market penetr
medday broad pipelin address metabol alter neurodegen diseas
abil target fatti acid synthesi prevent neuron degener medday evalu drug number differ
neurodegen diseas right on-going clinic trial demyelin neuropathi amyotroph later
sclerosi al adrenomyeloneuropathi medday also two candid preclin
stage develop treatment autism spectrum disord alzheim diseas respect target metabol
pathway brain may repres excit potenti avenu treat varieti neurolog neurodegen
june complet enrol trial evalu progress ms
decemb top-line result us-bas trial evalu progress ms
potenti nda submiss
tabl content
high-dos biotin enhanc myelin energi product
mechan action
caus pathogenesi
activ microglia
crisi demand
symptom diagnosi
price market share analysi
ms drug develop
competit landscap ms treatment
neurodegen diseas
demyelin neuropathi
amyotroph later sclerosi
adrenomyeloneuropathi
risk invest
medday privately-held french clinical-stag compani strive becom leader
space neurometabol compani focus develop treatment disord character
alter brain metabol medday lead program pharmaceutical-grad high-dos biotin formul
develop treatment primari secondari progress multipl sclerosi ppms/spm
demyelin creat greater energi demand neuron transmit action potenti due breakdown
saltatori conduct contribut neurodegen process high dose biotin thought
protect neurodegener boost neuron energi product via pathway biotin key
coenzym drive myelin synthesi medday report posit result one phase studi ms-spi
progress ms patient show revers diseas progress month
treat patient compar placebo-tr patient kind clinic activ never shown
progress ms patient medday current conduct studi confirm drug safeti
efficaci expect file approv us europ follow readout studi
result posit drug approv would well-posit captur substanti market
share due lack treatment option progress ms patient current one approv treatment
primari progress ms roch vtx ocrevu although drug target neuroinflamm thu
would effect patient medday target given larg size ms market combin
peak opportun medday us europ could readili exceed billion annual alreadi
prescrib roughli patient temporari author use atu franc
gener impress million revenu without market effort compani
medday also test demyelin neuropathi amyotroph later sclerosi al
adrenomyeloneuropathi two addit preclin asset current evalu potenti
therapi autism spectrum disord alzheim diseas medday full product
pipelin shown figur compani also advanc specmet platform march
acquisit profilom sa health divis form commissariat lenergi atomiqu
platform allow effici screen metabol pathway may relev pathogenes
neurodegen diseas platform provid medday potenti path futur pipelin expans
high-dos biotin enhanc myelin product
qizenday oral formul pharmaceutical-grad high-dos biotin also known vitamin
vitamin daili dose biotin use mg higher dose adequ
nutrit intak roughli recommend food nutrit board institut medicin
medday file approv ema base result ms-spi trial withdrew
applic late compani decid file approv us europ concurr follow
complet on-going phase trial alreadi prescrib roughli patient
temporari author use atu franc gener impress million revenu
without market effort compani trial second pivot phase trial enrol
patient site across world expect read decemb confirm
data obtain first pivot studi would repres major inflect point compani valuat
would like pave way approv us europ
mechan action high dose biotin thought protect demyelin
neurodegener role cofactor need activ number biotin-depend
carboxylas rate-limit enzym involv fatti acid synthesi myelin product
also provid intermedi requir energi product kreb tricarboxyl acid tca
figur model hypothes mechan action
figur propos mechan action biotin
sedel et al target demyelin virtual hypoxia high-dos biotin treatment progress multipl
tong structur function biotin-depend carboxylas cell mol life
high-dos biotin may promot remyelin biotin serv enzymat cofactor number
carboxylas includ two involv fatti acid biosynthesi acetyl-coenzym acetyl-coa carboxylas
carboxyl acetyl-coa produc malonyl-coa two-carbon
subunit need fatti acid elong malonyl-coa format lead fatti acid biosynthesi fatti acid
repres fundament compon myelin cytosol level malonyl-coa increas fatti acid
synthesi correspondingli central nervou system acc predominantli express
oligodendrocyt type glial cell gener protect myelin sheath damag destroy
high-dos biotin may contribut remyelin axon promot fatti acid biosynthesi role
cofactor therapi promot remyelin shown effect anim
model ms activ area research develop treat human
biotin may increas product axon normal myelin axon nerv impuls effici
conduct length axon myelin sheath damag energi requir propag signal
increas due decreas cluster voltage-g na channel state diminish saltatori conduct
axon greater energi demand conduct nerv signal thu requir greater atp product compound
observ ms patient increas dysfunct neuron mitochondria overal
suggest imbal atp avail energi demand requir axon mous model
biotin defici observ atp deficit compar normal high dose biotin
may abl resolv axon energi defici observ demyelin diseas part role
cofactor three carboxylas pyruv carboxylas pc propionyl-coa carboxylas pcc
coa carboxylas mcc involv atp-gener tca pc pcc mcc specif gener
kh regul mammalian acetyl-coenzym carboxylas annu nutr
 mechan biotin-depend enzym annu biochem
sherman brophi mechan axon ensheath myelin growth neurosci
foster malonyl-coa regul fatti acid synthesi oxid clin invest
mcgarri et al possibl role malonyl-coa regul hepat fatti acid oxid ketogenesi
mcgarri et al role malonyl-coa coordin fatti acid synthesi oxid isol rat
chakraborti ledeen fatti acid synthes enzym intrins myelin mol brain
tansey et al acetyl-coa carboxylas rat brain ii immunocytochem local dev brain
plemel et al remyelin therapi new direct challeng multipl sclerosi drug discov
heidker et al metabol pathway possibl therapeut target progress multipl sclerosi neural regen
deshmukh et al regen approach treatment multipl sclerosi natur
duncan et al extens remyelin lead function recoveri proc natl
bai et al hepatocyt growth factor mediat mesenchym stem cellinduc recoveri multipl sclerosi model
velazquez-arellano et al heurist model paradox effect biotin starvat carbon metabol gene
presenc abund glucos mol genet metab
hernndez-vzquez et al tempor develop genet metabol effect biotin depriv search
optimum time studi vitamin defici mol genet metab
hernndez-vzquez et al biotinidas knockout mice show cellular energi deficit alter carbon metabol
gene express similar nutrit biotin depriv clue pathogenesi human inherit disord mol
tong structur function biotin-depend carboxylas cell mol life
oxaloacet methylmalonyl-coa acetyl-coa respect three intermedi feed tca
cycl differ point
number enzym transcript regul biotin biotin may also bring therapeut
effect regul gene express vitro vivo preclin experi biotin shown
upregul express carboxylas interact pc add
anoth dimens biotin may promot remyelin energi product outsid role cofactor
specif mechan biotin use regul gene express postul consequ histon
biotin supplement diet increas tissu biotin level rat research studi effect biotin
supplement feed rat standard casein diet one supplement
biotin term weight biotin weight figur brain biotin level given rel biotin
supplement rat diet result show consist increas biotin tissu concentr
correspond biotin supplement among tissu examin includ skelet muscl brain heart
kidney lung test spleen base result present studi no-adverse-effect-level noael
biotin determin mg/kg lowest-observed-adverse-effect-level loael
determin mg/kg
eect excess biotin growth
figur tissu biotin level respons biotin supplement diet
note differ superscript letter indic signific differ data point
solorzano-varga et al holocarboxylas synthetas oblig particip biotin-medi regul
express biotin-depend carboxylas mrna level human cell proc natl sci
pacheco-alvarez et al paradox regul biotin util brain liver implic inherit
sawamura et al effect excess biotin administr growth urinari excret water-solubl
vitamin young rat biosci biotechnol biochem
biotin administr increas activ sever carboxylas effect daili administr biotin
placebo lymphocyt carboxylas activ examin diabet non-diabet patient
day carboxylas activ determin use vitro assay specif carboxylas isol patient
lymphocyt activ significantli increas biotin treatment diabet nondiabet group
shown figur similar result also observ pyruv carboxylas pc propionyl-coa carboxylas
pcc two carboxylas replenish intermedi import tca cycl data suggest
administr biotin could activ biotin-depend carboxylas contribut fatti acid biosynthesi well
energi product tca cycl human patient
figur acetyl-coa carboxylas activ respons biotin
biotin-depend carboxylas fatti acid biosynthesi knockout tissu
mous heart muscl show lower level fatti acid intermediari surprisingli
liver lipid accumul decreas determin histolog examin lipid vacuol oil-red-o tissu
stain lipid droplet examin epididym fat pad isol wild type mice
shown figur figur show fat pad knockout mice significantli smaller
wildtyp mice averag weight fat pad half one wild type mice gram
compar gram respect knockout mice also gener mutat
embryon lethal subsequ liver-specif adipos tissue-specif knockout mice produc
show similar phenotyp knockout mice name decreas malonyl-coa level decreas fatti
acid biosynthesi decreas lipid studi illumin fundament role biotin-
abu-elheiga et al continu fatti acid oxid reduc fat storag mice lack acetyl-coa
mao et al inactiv acetyl-coa carboxylas caus growth retard reduc lipid
accumul adipos tissu proc natl sci
mao et al liver-specif delet acetyl-coa carboxylas reduc hepat triglycerid accumul without
depend carboxylas gener key fatti acid progenitor malonyl-coa decreas
level malonyl-coa result decreas fatti acid biosynthesi accumul vivo
figur effect knockout mous fat pad
biotin depriv decreas express carboxylas human cell shown figur
human liver cancer cell subject biotin starvat indic time point use revers transcript
polymeras chain reaction rt-pcr shown biotin depriv led decreas mrna express
number differ carboxylas includ hc holocarboxylas synthetas pcca pcc
unaffect show repres experi show averag valu experi
mrna normal control -actin
figur express carboxylas respons biotin depriv
safeti profil medday demonstr safe well toler two phase clinic trial
multipl sclerosi msi-spi ms-on phase ii/iii trial addit ceo
frdric sedel inventor other clinician administ high dose biotin treatment
patient basal ganglia diseas bgd without safeti
msi-spi phase studi patient treat mg placebo month
option roll open-label extens studi addit month found
similar safeti profil placebo base incid advers event electrocardiogram analysi frequent
occur placebo-tr group includ urinari tract infect bronchiti
nasopharyng major report mild moder patient
placebo-tr patient experienc ms relaps consid seriou ae
electrocardiogram analysi reveal abnorm total treatment period
appear safe well-toler patient one import safeti find studi unintend
interfer treatment biotin-bas laboratori interfer lead misdiagnosi
subsequ treatment patient varieti differ condit includ grave diseas
addit safeti data msi-spi phase studi research collect data
open-label use franc roughli patient treat date patient
report major safeti concern
multipl sclerosi ms autoimmun diseas central nervou system affect brain spinal
cord optic nerv four type ms progressive-relaps secondary-progress primary-progress
relapsing-remit ms figur provid overview type ms
sedel et al target demyelin virtual hypoxia high-dos biotin treatment progress
deb et al biotin-respons basal ganglia diseas ethnic european novel mutat
tourbah et al high-dos biotin treatment progress multipl sclerosi randomis
barbesino misdiagnosi grave diseas appar sever hyperthyroid patient take biotin
sulaiman biotin treatment caus erron immunoassay result word caution clinician drug discov
figur type multipl sclerosi
patient diagnosi
steadi worsen diseas start
steadi worsen without sign relaps
relaps follow partial complet
worsen steadili without relaps
rrm patient
approxim ms patient initi diagnos relapsing-remit ms rrm
approxim patient diagnos rrm develop secondari progress spm within year
larg major patient first diagnos relapsing-remit ms rrm half rrm
patient later convert progress form diseas categor secondary-progress ms spm
roughli patient initi present progress ms smaller portion roughli exhibit progress
relaps diseas symptom diagnos progressive-relaps ms prm four differ type
ms differ cours diseas figur depict progress diseas type
figur diseas progress time differ type ms
cours progress ms expert describ diseas activ show mri activ
indic new lesion activ evid mri patient exhibit inflamm evidenc
presenc relaps new lesion classifi activ form diseas
expert also propos diseas categor gradual diseas progress mark worsen
symptom without full breakdown progress ms phenotyp shown figur
hersh multipl sclerosi cleveland clinic continu educ diseas manag
ontaneda progress multipl sclerosi curr opin neurolog
lublin et al defin clinic cours multipl sclerosi revis neurolog
new classif propos expert field accur describ differ progress ms
phenotyp allow improv identif patient clinic trial
figur breakdown ms classif phenotyp
activ determin clinic relaps assess least annual and/or mri activ contrast-enhanc lesion new
unequivoc enlarg lesion progress measur clinic evalu assess least annual
caus pathogenesi ms chronic neurolog diseas result episod immune-medi attack
myelin-oligodendrocyt complex throughout relaps form ms immun system select
target myelin sheath surround nerv fiber caus scar also known sclerosi damag fiber
damag larg collect axon brain creat distinct ms lesion within white matter
brain mri imag gadolinium stain help visual lesion import part
diagnost process addit lesion individu rrm experi signific breakdown blood
brain barrier bbb period relaps meanwhil progress form ms break-down blood brain
barrier less common patient instead exhibit degener white grey ms patient
exhibit fewer overal lesion lesion show less enhanc follow stain
caus ms well understood diseas progress highli variabl among affect individu
two main pathophysiolog compon ms inflamm involv format lesion
neurodegener gener relaps ms character period intens focal inflamm
progress ms character on-going neurodegener chronic inflamm
exact caus remain unknown multipl hypothes ms pathogenesi one hypothesi known
outside-in hypothesi propos neurodegener occur result inflammatori
bradl lassman progress multipl sclerosi semin immunopathol
ontaneda progress multipl sclerosi curr opinion neurol
khale et al lesion enhanc diminish time primari progress multipl sclerosi multipl sclerosi
prez-cerd et al link inflamm neurodegener progress multipl sclerosi multipl sclerosi
demyelin disord
demyelin believ trigger cascad event activ microglia mitochondri damag
bring neurodegener altern hypothesi known insid hypothesi propos
ms actual better character primarili degen diseas initi begin degener myelin
lead neuroinflamm regardless come first like inflamm degener
continu drive one anoth cours diseas
type ms acut ms lesion consist lymphocyt infiltr cross blood-brain inflammatori
infiltr larg consist cell cell activ microglia relaps ms focal
demyelin break-down blood brain barrier promin surround lesion meanwhil
progress ms less breakdown blood brain barrier instead degener white grey
matter nearbi figur illustr cross inflammatori infiltr blood born t-
cell monocyt macrophag past blood brain barrier bbb relaps progress
figur central nervou system inflamm differ type ms
relaps rrm open bbb allow lymphocyt infiltr enter
cell releas proinflammatori factor caus microgli activ chronic microgli activ
lead demyelin eventu neuron degener remiss bbb repair
decreas level lymphocyt infiltr subsequ less activ microglia
progress ms lymphocyt infiltr cell trap behind bbb continu releas proinflammatori
factor act microglia relaps progress form ms involv inflamm gadolinium-
enhanc gener evid magnet reson imag mri scan patient relaps form
diseas gadolinium enhanc larg visibl signific break blood
minagar alexand blood-brain barrier disrupt multipl sclerosi multipl sclerosi
luessi et al neurodegener multipl sclerosi novel treatment strategi expert review
ontaneda progress multipl sclerosi curr opin neurolog
bradl lassman progress multipl sclerosi semin immunopathol
minagar alexand blood-brain barrier disrupt multipl sclerosi multipl sclerosi
brain barrier absenc gadolinium enhanc suggest inflamm accompani disrupt
blood brain barrier progress form diseas addit progress ms pattern
inflamm differ relaps inflammatori cell typic found perivascular cuff
rather parenchyma howev activ microglia occur similar locat relaps ms
suggest proinflammatori factor diffus travel space caus microgli
activ exact mechan behind diffus proinflammatori factor lesion site fulli
understood also progress ms inflammatori molecul becom trap behind bbb form follicle-lik
aggreg aggreg present cortic demyelin neurodegener promin
addit inflamm occur site acut lesion ms also signific degener
neuron white grey matter causal relationship demyelin degener remain
unclear research suggest microglia activ mitochondri damag ionic imbal contribut
activ microglia microglia first cell respond injuri within microglia respond
injuri exhibit phagocyt phenotyp describ activ multipl sclerosi activ
microglia found within lesion releas pro-inflammatori signal like
tumor necrosi factor-a tnf-a nitric oxid reactiv oxygen speci ro reactiv nitrogen speci
activ oxidas myeloperoxidas xanthin nadph oxidas microglia
mitochondri damag neurodegener ms like involv mitochondri damag mitochondria
especi vulner oxid chronic activ microglia may therefor affect mitochondri
function ro rn togeth interfer function cytochrom oxidas
part respiratori chain specif activ complex iv respiratori chain reduc
mitochondria surround ms lesion ro may also damag mitochondri dna mtdna lead
mitochondri damag eventu neuron death
nucleat cell oligodendrocyt damag mitochondria lead releas apoptosis-induc factor
aif shown figur aif travel nucleu induc dna damag lead activ poli
adp-ribos polymeras tri repair damag actual lead
greater energi demand cell met energi defici reach certain threshold cell
bradl lassman progress multipl sclerosi semin immunopathol
luessi et al neurodegener multipl sclerosi novel treatment strategi expert review
prez-cerd et al link inflamm neurodegener progress multipl sclerosi multipl sclerosi
demyelin disord
correal role microgli activ diseas progress multipl sclerosi journal
prez-cerd et al link inflamm neurodegener progress multipl sclerosi multipl sclerosi
demyelin disord
figur effect mitochondri injuri oligodendrocyt
crisi energi demand myelin sheath similar mitochondria vulner pro-inflammatori cytokin
ro rn therefor releas molecul follow chronic microglia activ may directli lead
loss myelin sheath surround neuron loss myelin bring number effect includ increas
neuron energi demand fulli myelin neuron sodium channel mostli concentr along node
ranvier gap neuron undergo demyelin ms sodium
channel express across entir length axon shown figur cell undergo crisi
energi demand sodium accumul excess level cell abl remov sodium due lack
atp follow mitochondri damag excess sodium caus addit damag atp level may
alreadi decreas due ross damag mtdna worsen energi crisi occur axon
number ionic imbal contribut crisi energi demand calcium accumul excess
cell due influx calcium exchang glutam receptor voltage-g calcium
channel vgcc present excess level calcium activ proteas calpain dissolv axon
protein normal respons key transport process within axon follow
degrad critic protein cell may undergo apoptosi
freeman et al mechan sodium channel cluster influenc axon impuls conduct cell mol
lassman et al progress multipl sclerosi patholog pathogenesi diseas mechan ms
figur effect energi defici ionic imbal within axon
symptom diagnosi multipl sclerosi diagnos use varieti clinic measur includ medic
histori neurolog exam magnet reson imag mri brain evok potenti test analysi
cerebrospin fluid ms diagnosi publish criteria provid guidelin regard
clinic metric clearest measur relaps ms relaps attack last least hour
absenc fever infect lesion brain presenc two attack two
lesion suffici make posit diagnosi patient fewer relaps fewer lesion requir addit test
confirm ms progress ms patient experi relaps attack instead show slow worsen
diseas symptom time therefor order diagnos progress ms patient must exhibit one year
diseas progress two follow lesion brain characterist ms two similar
lesion spinal cord spinal fluid oligoclon band elev igg diseas worsen
may happen slowli first diagnosi primari progress ms may two three year longer relapsing-
figur show exampl brain lesion patient relaps ms top panel show mri imag
patient primari progress ms arrow point brain lesion area inflamm myelin
destruct bottom panel enlarg imag two lesion
 et al recommend diagnost criteria multipl sclerosi guidelin
diagnosi multipl sclerosi annal neurolog
figur show exampl neurodegener patient primari progress age patient
show lesion abnorm larg vesicl seven year later age patient show similar size lesion
increas neurodegener enlarg vesicl
van der kolk et al clinic applic mri brain european journal radiolog
antel et al primari progress multipl sclerosi part ms diseas spectrum separ diseas entiti acta
treatment cur therapi avail ms exist treatment rrm focu decreas
frequenc flare-up shorten durat allevi symptom diseas order improv
patient qualiti life current one drug approv primari progress ms ppm unit
state one approv secondari progress ms spm drug recent approv ppm ocrevu
target antigen cell drug approv spm mitoxantron although rare use
due potenti cardiac toxic risk induc secondari leukemia
ocrevu ocrelizumab roch vtx march ocrevu becam first drug receiv approv
unit state treatment primari progress ms addit januari ocrevu becam
first drug approv treatment earli primari progress ms europ note ocrevu approv
europ restrict patient popul accord ema ocrevu approv patient
earli stage primari progress ms base diseas durat level disabl sinc ocrevu drug target
neuroinflamm like use patient target medday
ocrevu believ interfer immune-medi attack myelin sheath occur cours ms
pathophysiolog ocrevu monoclon antibodi bind antigen normal malign cell
cell play critic role ms pathogenesi exactli involv remain unknown cell may
involv follow pathogen process ms product autoantibodi present antigen
secret cell also present inflammatori lesion therefor may relat
surround demyelin neurodegener antigen found surfac pre- matur
memori cell cell precursor plasma cell antibodi ocrevu abl target
kill cell bind antigen howev ocrevu bind cell precursor plasma
cell earliest form cell bodi may still produc healthi cell drug administ
intraven infus deliv everi six month
roch complet phase trial oratorio ppm patient evalu efficaci safeti
ocrevu double-blind placebo-control trial patient random ratio receiv either
ocrevu placebo ocrevu deliv dosag mg two mg intraven infus two week apart
everi week minimum week primari endpoint studi time onset disabl
progress due ms confirm present follow neurolog assess perform week later
disabl progress defin increas edss score least point baselin baselin edss
score point less increas least point baselin edss score point
studi show ocrevus-tr patient experienc confirm disabl progress compar
placebo-tr patient translat risk reduct ocrevus-tr patient statist
treatment ocrevu gener safe well-toler patient experi infusion-sit reaction
infect event mostli mild moder sever oratorio trial patient
ocrevus-tr group report infect compar placebo-tr common form
infect upper respiratori tract infect ocrevus-tr patient show evid neoplasm
montalban al ocrelizumab versu placebo primari progress multipl sclerosi new england journal
montalban al ocrelizumab versu placebo primari progress multipl sclerosi new england journal
compar placebo-tr patient also note women treat ocrevu develop breast
cancer compar zero placebo-tr women suggest patient treat ocrevu may elev
risk develop cancer risk note ocrevu fda label
epidemiolog epidemiolog ms complex famili histori effect risk develop
ms rel ms patient higher rate develop women like
relaps ms men affect individu diagnos third fourth decad life
median age rrm onset roughli year age age ratio femal diseas
meanwhil onset spm roughli year rrm male femal equal affect
ms common autoimmun diseas affect roughli million diagnos individu
accord cleveland clinic roughli ms patient us estim
ms patient europ total ms patient popul initi present primari progress ms roughli
half rrm patient transit spm point cours diseas patient convert rrm
spm rate roughli per total number individu progress ms estim
least estim averag annual cost associ ms treatment per diagnos
individu
preval vari wide make hard estim accur number ms patient world-wide europ
north america preval may high greater eastern asia sub-saharan africa
preval low research suggest preval increas individu
equat although notion recent combin better
diagnost techniqu prolong surviv led increas preval world-wide
market size intend patient progress ms character activ
state patient popul roughli individu world-wide figur estim target
patient popul us europ base follow assumpt
weinshenk epidemiolog multipl sclerosi neurolog clinic
wingerchuck multipl sclerosi current emerg disease-modifi therapi treatment
goldmann prinz role microglia autoimmun clinic development immunolog
antel et al primari progress multipl sclerosi part ms diseas spectrum separ diseas entiti acta
ontaneda al progress multipl sclerosi prospect diseas therapi repair restor function
kobelt et al cost qualiti life patient multipl sclerosi europ neurol neurosurg psychiatri
leray et al epidemiolog multipl sclerosi neurol pari
kock-henriksen srensen chang demograph pattern multipl sclerosi epidemiolog
ms patient estim roughli ms patient us patient
progress ms assum roughli ms patient either primari secondari progress
non-act state assum roughli progress ms patient inact state
figur target patient popul us europ
us europ alon roughli ms patient potenti candid use
current treatment approv progress ms roch vtx ocrevu ocrelizumab howev
import note ocrevu intend treat progress ms patient activ state
drug target inflamm meanwhil target neurodegener approv
drug given lack treatment option progress ms medday well posit captur substanti
portion us european market ultim approv sale ms drug total
billion underscor larg market exist ms therapi
price market share analysi wholesal acquisit cost wac approv ms drug rang
recent entrant market command premium price shown figur
high-dos biotin formul product like price significantli lower compar current
figur annual cost ms drug
note first treatment cours second treatment cours month later report
figur conduct scenario analysi possibl peak penetr medday captur
market share us europ would translat total revenu compani billion
sale underscor larg market opportun given lack treatment option patient
popul may reflect conserv estim analysi base follow assumpt
market penetr scenario analysi use peak penetr
base lack therapi progress non-inflammatori ms believ reason
rang assum peak penetr
target patient popul assum total elig patient popul us
europ
price assum price us europ
figur scenario analysi market penetr total market opportun
medday conduct sever clinic trial assess treatment progress multipl sclerosi
research shown evid slow revers disabl progress progress ms patient
data clinic trial shown safe well-toler suggest biotin may effect
target certain aspect neurodegener medday ms-spi trial patient show
confirm revers diseas progress month compar placebo-tr patient trial also
provid addit evid treatment safe well-toler patient medday current
evalu second phase clinic trial expect report top-line result late result
posit approv may first approv treatment target neurodegener
lead sustain improv patient progress ms base result mps-spi trial medday
submit applic approv europ howev novemb medday withdrew
applic follow concern rais committe medicin product human use chmp
sampl size efficaci data overal risk-benefit profil drug chmp also said inform
need regard drug method absorpt remov within bodi medday plan re-submit
submit nda support data ms-spi trial
phase proof-of-concept studi high-dos biotin ms
medday complet phase trial franc test efficaci safeti patient primari
secondari progress preliminari data studi suggest biotin may impact diseas
progress among patient progress ms overal patient show form clinic
improv follow treatment high dose biotin base posit result studi research
continu evalu high dose biotin treatment progress ms clinic trial
sedel et al high dose biotin chronic progress multipl sclerosi pilot studi multipl sclerosi relat
trial design open-label proof-of-concept studi assess efficaci safeti patient
progress ms patient primari secondari progress ms exhibit minimum diseas
progress month treat period time rang month mean length
treatment month dose biotin rang mg mg per day median dose mg per
day divid three daili dose patient evalu base specif clinic condit four patient
chronic optic neuropathi assess use test visual acuiti va goldmann perimetri visual
evok potenti vep singl patient homonym hemianopia assess use humphrey autom
perimetri patient spinal cord involv assess base walk distanc test expand
disabl statu scale edss time-to-walk feet test
trial result patient includ studi patient ppm spm four patient
optic nerv involv three patient show improv visual acuiti maintain time
singl patient homonym hemianopia exhibit improv humphrey visual field analyz test
month month patient spinal cord involv show clinic improv
delay time improv rang month patient show improv
dose mg biotin patient show addit improv dosag increas mg
patient began show improv mg dose remain patient show improv
receiv mg dose across patient edss score significantli improv patient total
patient least one ms relaps relaps symptom similar observ initi
treatment biotin patient report advers event cours treatment patient report
transient diarrhea patient die follow cardiac failur month treatment biotin
follow-up patient found mild aortic valvulopathi research find relationship
onset treatment cardiac abnorm death addit patient die follow pneumopathi follow
sigmoid volvulu surgeri relationship found biotin treatment death
phase studi test chronic visual loss relat optic neuriti ms ms-on trial
medday complet phase trial franc uk assess whether improv patient recoveri
follow incomplet remiss acut relaps patient progress worsen symptom trial
meet primari endpoint prospect subgroup analysi later indic may provid
benefit patient progress optic neuriti overal exhibit strong safeti toler profil
efficaci ms patient perman vision progress relapsing-remit
ms patient includ trial inclus criteria requir patient meet one follow two condit
fix vision loss month follow acut optic neuriti previou year non-progress
ms patient show progress visual loss assess differ visit previou year progress optic
tourbah et al effect high dose biotin chronic visual loss relat optic neuriti multipl
sclerosi ms-on result pivot random doubl mask placebo-control studi american academi neurolog
patient random ratio receiv either daili dose mg placebo treatment
period week primari endpoint mean chang baselin end treatment
contrast visual acuiti va patient eye origin show worst visual acuiti sever
progress endpoint includ chang visual evok potenti autom visual field perimetri optic
coher tomographi patient-report outcom measur
trial result result suggest treat patient exhibit slight improv placebo-
treat patent treatment group improv averag letter test visual acuiti compar
averag improv letter placebo treatment group differ group reach
statist signific open-label extens patient continu show improv visual
acuiti test patient show improv letter patient switch placebo
show improv letter prospect subgroup analysi show patient
progress optic neuriti may benefit treatment progress patient treat
show improv letter compar progress patent treat placebo
show declin letter time period
safeti overal well-toler patient placebo treatment group show similar
incid rate advers event notabl differ abnorm laboratori data
patient indic high-dos biotin might affect result immunoassay use biotinyl
antibodi substrat
mps-spi phase studi test efficaci not-act spinal ms patient
medday complet phase trial franc assess efficaci safeti progress ms patient
result suggest treatment abl revers diseas progress patient data indic
strong risk-benefit profil well-toler patient
trial design random double-blind placebo-control pivot phase trial mps-spi measur
efficaci spinal ms inclus criteria requir patient exhibit diseas progress
within past two year lack inflammatori activ indic patient activ diseas
state patient random ratio receiv either dose mg three time per day
placebo month patient enter extens studi patient receiv
primari endpoint proport patient show improv either expand disabl
statu scale edss time-to-walk feet test month confirm month improv
defin decreas point point edss baselin score respect
decreas time compar best edss valu record either screen
random visit confirm improv edss interpret indic revers diseas
progress secondari endpoint includ follow assess month
clinic global impress chang assess clinician cgi patient sgi
trial result patient show statist signific improv placebo-tr patient
suggest may effect slow halt diseas progress ms
treat patient show revers diseas progress improv month confirm month
compar placebo-tr patient differ group statist signific
patient treat first month continu
treatment extens phase show improv month confirm month
group patient treat placebo first month later switch
treatment extens phase show improv month confirm month
figur display improv result placebo-tr group double-blind extens
figur patient improv double-blind extens phase studi
treat group show mean decreas edss point placebo group show mean
increas edss point differ group statist signific
treat patient also significantli improv cgi sgi score compar placebo group mean cgi
score patient compar placebo group mean sgi
score compar placebo group month signific differ
cgi sgi score placebo group placebo group show improv cgi
sgi score treatment extens phase data msw show
tourbah et al high-dos biotin treatment progress multipl sclerosi random
signific differ group
safeti incid advers event similar placebo treatment group major
consid mild moder sever double-blind portion studi
treat patient experienc advers evet compar placebo-tr patient open-label
extens phase patient experienc advers event compar patient
origin treat placebo urinari tract infect uti common advers event
patient placebo-tr patient experienc uti double-blind portion
studi common advers event bronchiti nasopharyng hyperthyroid one patient
develop mucocutaen rash origin thought relat howev subsequ test
rule relationship treatment one death suicid report arm
consid relat treatment ae occur one patient ms relaps
double-blind phase ms relaps occur patient treatment group placebo
group extens phase ms relaps occur patient origin receiv
patient origin receiv placebo
pivot multicent phase studi test efficaci multipl sclerosi
medday current run second pivot phase trial patient progress ms trial design similar
previou phase studi ms-spi present studi aim enrol larger patient popul
treatment period extend top-line result expect late
trial design random double-blind placebo-control pivot phase trial aim confirm
safeti efficaci revers cours progress medday expect enrol patient
primari secondari progress ms evid disabl progress within past two year
evid inflamm double-blind portion studi patient random ratio receiv
either dose mg three time day placebo treatment least month double-blind
period end last recruit patient reach endpoint open-label extens portion
studi patient receiv dose mg three time day
primari endpoint proport patient show improv either expand disabl statu
scale edss time-to-walk feet test month confirm month improv
defin decreas point point edss baselin score respect
decreas time compar best edss valu record either screen
random visit secondari endpoint includ follow
time edss progress confirm week
clinic global impress chang improv cgi-i score
mean chang
ms drug develop
due high unmet need progress ms patient number compani develop treatment
popul figur provid overview drug develop progress ms medday candid
second phase pivot trial well-posit becom first approv drug target neurodegener
popul progress ms patient drug ultim approv uniqu mechan
action would allow combin therapi treatment one list
figur drug develop ms
siponimod novarti develop siponimod select
modul receptor g-protein coupl receptor affin
lysophospholipid lipid secondari messeng express
lymphocyt believ play key role egress lymphocyt form novarti nyse
gilenya fingolimod approv drug rrm target receptor drug develop
target receptor either specif target and/or receptor subtyp drug bind
lead inhibit certain lymphocyt migrat inflamm site therefor lead
decreas inflammatori activ drug bind lead activ certain cell allow
increas remyelin prevent impair compar gilenya agonist
develop expect bind fewer receptor subtyp therefor less potenti off-target effect
garri et al receptor signal cell traffick beyond immunolog
garri et al receptor signal cell traffick beyond immunolog
number drug develop ms target receptor includ celgen
celg ozanimod johnson johnson nyse ponesimod mitsubishi tanab pharma tyo
novarti studi siponimod pivot expand phase trial investig safeti efficaci
siponimod patient secondari progress major secondari progress ms patient
enrol studi non-relaps activ ms patient random ratio receiv either
mg siponimod placebo core studi last three year patient given option enter
open-label extens ole studi addit month ole portion studi current on-going
primari endpoint double-blind portion trial time three-month confirm disabl
progress use expand disabl statu scale edss activ versu placebo treatment group secondari
endpoint includ follow time confirm worsen greater time walk test
lesion volum annual relaps rate safeti toler siponimod also measur
siponimod treatment group show reduc risk three-month confirm disabl progress compar
placebo-tr group siponimod-tr patient continu show reduc risk disabl
progress confirm month addit siponimod-tr patient show signific improv
placebo annual relaps rate chang brain volum chang lesion baselin non-
signific differ group test result soon publish novarti
expect file fda approv siponimod treatment secondari progress ms first quarter
simvastatin statin fda-approv treatment hypercholesterolemia high cholesterol level statin
work inhibit coenzym reductas stop biosynthesi
statin also believ immunomodulatori anti-inflammatori neuroprotect effect
abil inhibit isoprenyl gtp-bind protein
double-blind phase ii studi secondari progress ms patient research evalu simvastatin
treatment progress form patient random receiv either mg simvastatin placebo
month primari endpoint annual rate whole-brain atrophi measur magnet reson
imag mri scan secondari endpoint includ chang edss multipl sclerosi function composit scale
msfc multipl sclerosi impact relaps frequenc cholesterol level intracellular
cytokin express also assess result show treatment simvastatin led reduct brain
atrophi compar placebo-tr patient month simvastatin-tr patient
exhibit lower rate brain atrophi compar placebo-tr patient simvastatin-tr patient also show
signific improv placebo patient edss statist signific
differ simvastatin placebo-tr patient msfc although trend toward
improv simvastatin treatment group signific differ group
intracellular cytokin express cholesterol level lower simvastatin-tr group expect base
statin role inhibit cholesterol biosynthesi treatment simvastatin safe well-toler
expect given strong safeti profil drug treatment hypercholesterolemia follow
ciurleo et al role statin treatment multipl sclerosi pharmacolog research
chataway et al effect high-dos simvastatin brain atrophi disabl secondari progress multipl
posit phase ii result research investig efficaci simvastatin phase trial
secondari progress ms patient long-term studi expect top-line result
masitinib ab scienc develop masitinib treatment progress ms masitinib tyrosin kinas
inhibitor target immun cell target immun cell masitinib may prevent immun system attack
myelin sheath characterist ms pathogenesi note masitinib evalu number
indic includ amyotroph later sclerosi fail show convinc sign efficaci
double-blind random placebo-control phase ii studi research evalu multipl dose masitinib
progress ms patient primari secondari progress ms treat dose
masitinib rang mg/kg/day mg/kg/day masitinib placebo minimum month patient
permit increas masitinib dose suffici respons treatment patient exhibit
toxic primari endpoint chang multipl sclerosi function composit msfc baselin
end treatment secondari endpoint includ chang time walk test expand
disabl statu scale edss test pace auditori addit test result
show overal posit trend toward improv masitinib-tr patient result statist
signific averag chang msfc baselin masitinib treatment group compar
placebo treatment group differ group statist signific
howev trend toward greater improv masitinib-treat group seen third month
continu month treatment addit masitinib-tr patient show clinic respons
treatment defin greater improv msfc score baselin compar
placebo-tr patient show clinic respons treatment group show declin
masitinib-tr group appear slower declin masitinib-tr patient show improv
placebo-treat patient show improv edss score remain stabl
cours treatment group
given posit trend seen phase ii data research evalu masitinib random double-
blind placebo-control phase trial evalu drug safeti efficaci primari
secondari progress ms patient week patient random ratio receiv masitinib placebo
treatment masitinib dose cohort evalu mg/kg/day mg/kg/day escal
mg/kg/day primari endpoint studi chang edss score week treatment top-line result
expect second quarter
opicinumab shire shpg develop
opicinumab antibodi drug target protein protein shown inhibit
differenti oligodendrocyt cell key step neuron myelin anim model antagon
led increas remyelin shire complet two phase ii trial efficaci
safeti drug treatment ms
random placebo-control studi patient relapsing-remit secondari progress ms
treat placebo opicinumab dose mg/kg via intraven inject deliv everi
four week total inject patient simultan treat interferon-bas drug ifn
primari endpoint percentag patient experienc confirm improv disabl week
follow first edss scale use measur disabl statu baselin patient exhibit
mild moder disabl score rang
trial miss primari endpoint statist signific differ placebo
opicinumab-tr patient follow treatment placebo group patient improv edss
score mg/kg dose group show respect improv
edss score baselin lack dose respons suggest opicinumab
treatment effect addit increas occurr seriou advers event sae
opicinumab-tr group mg/kg mg/kg opicinumab treat group sae rate
compar rate placebo-tr retrospect post hoc analysi indic opicinumab
greatest effect patient diseas shorter period time mri scan indic
remyelin possibl
shire launch phase iib studi studi opicinumab add-on therapi relapsing-
remit ms patient studi current recruit
ibudilast oral formul ibudilast inhibitor
macrophag migrat inhibitori factor mif molecul inhibitori activ believ prevent
releas pro-inflammatori cytokin attenu glial cell activ approv market
japan south korea treatment asthma cerebrovascular diseas name keta
random placebo-control phase ii studi research evalu treatment progress
studi aim evalu safeti toler activ administ primari
secondari progress ms patient patient random ratio receiv either maximum
dose mg/day separ two daili dose placebo week random stratifi
whether patient take disease-modifi therapi glatiram acet interferon beta whether
patient primari secondari ms primari endpoint chang brain atrophi base quantit
magnet reson imag mri use brain parenchym fraction bpf versu placebo-tr
patient measur safeti toler compar placebo secondari endpoint includ
measur disabl cortic atrophi cognit impair quality-of-lif neuropath pain trial met
primari secondari endpoint treatment led reduct brain atrophi compar
placebo differ group statist signific rate seriou advers event
differ significantli placebo-tr patient common treatment-rel
advers event gastrointestin event occur frequent group upper
respiratori tract infect occur frequent placebo group
efficaci result phase synergi studi treatment disabl multipl sclerosi
monoclon antibodi opicinumab american academi neurolog annual meet
mccroskeri et al safeti toler opicinumab relaps multipl sclerosi phase synergi
 et al sprint-ms/nn phase ii trial ibudilast progress ms top-lin result multipl sclerosi
competit landscap ms treatment
failur rrm drug form ms despit approv class drug rrm
remain urgent need therapi address progress form diseas mani drug
effect rrm approv indic shown effect progress ms
decad drug candid progress ms fail gener posit treatment effect control clinic
trial progress ms involv differ pathophysiolog rrm possibl account high rate failur
success rrm drug test progress rrm consid immune-medi
inflammatori disord progress diseas character on-going perman neurodegener
roch vtx ocrevu recent becam first avail treatment progress ms strong efficaci
phase trial novarti nyse siponimod show encourag efficaci result phase trial
secondari progress ms patient may becom second approv treatment progress ms howev
similar rrm treatment ocrevu siponimod target inflammatori aspect progress ms
therefor may benefici progress ms patient activ diseas state show activ inflammatori
lack treatment target neurodegener form ms remain unmet need
treatment address neurodegen aspect multipl sclerosi within ms popul
approxim primari progress ms patient show sign activ inflammatori lesion
roughli primari progress ms patient patient primarili experi progress
neurodegener continu worsen diseas symptom therefor treatment ocrevu siponimod
may suffici meet need group patient fact current approv disease-
modifi treatment target neurodegener efficaci medday confirm second
pivot phase trial treatment could becom first approv treatment neurodegener progress
uniqu mechan action target demyelin neurodegener
mechan action target inflammatori demyelin neurodegener target inflammatori
demyelin activ tca cycl increas mitochondria citrat level turn lead
increas synthesi fatti acid use rebuild myelin sheath process shown
mcfarland hf martin multipl sclerosi complic pictur autoimmun natur immunolog
figur biotin role drive product myelin
time target neurodegener offset increas energi demand demyelin
axon demyelin axon requir atp may enter hypoxia-lik state energi demand met
lead cell death eventu progress neurodegener throughout brain enhanc energi
level neuron may slow neurodegener process illustr figur
figur biotin role prevent level neuron
product target inflammatori demyelin progress neurodegener
confirm effect second phase trial approv may wide use treatment
neurodegen diseas
abil target fatti acid synthesi prevent neuron degener medday
evalu drug number neurodegen diseas right on-going clinic trial
demyelin neuropathi amyotroph later sclerosi al adrenomyeloneuropathi
demyelin neuropathi medday investig treatment demyelin
neuropathi includ chronic inflammatori demyelin polyneuropathi cidp peripher neuropathi
charcot-marie-tooth diseas type diseas character pathogenesi involv damag
myelin sheath current corticosteroid commonli use first-lin treatment diseas howev
long-term use corticosteroid limit due side effect treatment option includ intraven
immunoglobulin ivig plasma exchang due highli debilit natur diseas lack
varieti treatment option mani treatment candid current evalu clinic trial
may abl drive fatti acid synthesi therefor increas product myelin medday
studi effect motor sensori conduct patient demyelin neuropathi
open-label phase i/ii studi research recruit patient follow condit chronic
inflammatori demyelin polyneuropathi cidp peripher neuropathi charcot-marie-tooth diseas type
patient receiv week primari endpoint studi chang motor nerv
conduct veloc distal latenc wave latenc measur nerv conduct veloc length motor nerv
potenti patient classifi clinic respond show greater improv least
criteria secondari endpoint includ follow measur overal neuropathi limit scale
minut walk test posturoemtri supernorm strength-dur time constant rheobas refractori min-
max absolut refractori period top-line result studi expect late
amyotroph later sclerosi amyotroph later sclerosi al character degener
upper lower motor neuron subsequ muscl atrophi exact mechan action behind
neurodegener remain unknown current treatment diseas
potenti abil prevent neuron degener medday studi safeti efficaci
al
research evalu safeti efficaci al patient random placebo-control
double-blind phase ii patient random ratio receiv either dose mg/day
placebo month primari endpoint occurr advers event result laboratori test
secondari endpoint chang motor disabl diseas sever slow vital capac maxim inspiratori
pressur mip sniff nasal inspiratori pressur snip weight trial finish enrol result
yet releas
adrenomyeloneuropathi adrenomyeloneuropathi adult-onset form x-link
adrenoleukodystrophi ald diseas result mutat gene lead impair long-
chain fatti acid transport peroxisom subsequ chronic patient may either diseas
pathogenesi involv spinal cord milder form diseas pathogenesi involv
spinal cord brain sever form diseas current disease-modifi treatment
diseas follow encourag preclin data medday investig treatment
random double-blind placebo-control phase ii/iii europe-bas trial research investig
efficaci treatment patient studi enrol patient random
receiv either dose mg/day placebo month patient given
option enrol open-label extens studi primari endpoint mean chang
minut walk test month baselin secondari endpoint includ follow measur
proport patient greater improv proport patient greater
improv time-to-walk feet test mean chang time up-and-go test qualiti life
questionnair evalu urinari function result trial publicli releas
medday two addit current test preclin studi
compani pursu autism spectrum disord expect launch proof-of-concept
studi medday plan target alzheim diseas compani yet provid guidanc
plan program
march medday acquir profilom inc compani develop research
platform identifi abnorm metabol pathway relev pathogenes neurodegen
march medday advanc specmet platform acquisit profilom sa health
divis form commissariat lenergi atomiqu platform call specmet platform
screen patient cerebrospin fluid csf identifi metabol abnorm platform allow identif
new therapeut target new metabol biomark shown figur medday current maintain
biobank roughli csf sampl correspond neurodegen diseas diseas character
rare inborn error metabol addit collabor commissariat lenergi atomiqu
medday set liquid chromatography-mass spectrometri lc-m screen evalu roughli compound
csf sampl
dubois-dalq et al neurobiolog x-link adrenoleukodystrophi demyelin peroxisom disord
trend neurosci
figur overview specmet platform
addit patent protect use high-dos biotin treatment multipl sclerosi medday
also agreement am dsm exclus access commerci sourc high-
dose pharmaceutical-grad biotin mani over-the-count over-the-counter sourc biotin contain impur
need dose order bring clinic effect prevent over-the-counter biotin use substitut
medday patent portfolio shown figur
biotin treatment ms
biotin treatment x-
chief execut offic co-found
dr frdric sedel md phd co-found chief execut offic medday train neurologist
neuroscientist complet resid pari phd ecol normal suprieur pari studi
inborn error metabol iem prof saudubray necker children hospit pari
dr sedel found coordin neurometabol depart piti-salptrir hospit dedic
treat adult iem dr sedel part refer centr lysosom diseas vice presid
french societi iem presid ssiem european adult metabol group publish
around peer-review articl mostli dedic adult neurolog co-found medday
guillaum brion becam fulli dedic ceo novemb
chief oper offic co-found
dr guillaum brion md co-found chief oper offic medday train physician
pari medic school pharmaceut market found develop servic compani field
clinic develop pharmaceut industri gain broad experi set manag
clinic trial first human administr larg multi-cent multi-n pivot clinic trial
group de recherch et detud scientifiqu gre tar versu clinic research servic farma
research dedic earli clinic develop held busi develop posit ucti
mcbio merieux central biolog central laboratori servic compani work clinic
research physician medic analyst busi develop orphan europ part recordati group co-
found medday frdric sedel acceler develop new drug diseas central
nervou system high unmet medic need
dr robert lasser md chief medic offic medday train geriatr psychiatrist clinic
neuroscientist year experi pharmaceut industri earli train biochemistri
dartmouth colleg obtain md degre boston univers train mgh mclean adult
psychiatri resid program harvard univers us nation institut fellowship
join industri sinc time robert held leadership role across neurosci clinic develop
medic affair global commerci multipl top pharmaceut manufactur includ novarti
roch johnson johnson shire author scientif public schizophrenia alzheim
diseas late-lif depress adhd robert ad formal busi train wharton school
risk invest
consid invest medday high-risk invest medday
clinical-stag compani current fda approv drug portfolio compani
develop treatment indic medday well medday gener posit data one
pivot studi patient progress multipl sclerosi may translat second pivot studi
indic compani medday may unabl obtain suffici capit fund plan
develop program market launch substanti regulatori risk associ develop
drug medday may receiv fda and/or ema approv candid despit signific time
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect
secur subject compani research analyst cover research view express report accur
reflect person view subject secur subject compani part research
analyst compens directli indirectli relat specif recommend view express research
analyst report
